



AaviGen presents its novel heart-specific AAV capsids generated by its next-generation cardiac AAV platform

Heidelberg, Germany - December 14, 2022 – For the first time, AaviGen presented data on its novel heart-specific adeno-associated viral (AAV) vector portfolio generated by its *next-generation Cardiac AAV Platform (next-CAP)* to an international audience. The invited presentation took place at the *Cell & Gene Therapy Meeting* (December 14 - 15, 2022) hosted by the Economic Partnership Initiative between Baden-Württemberg and United Kingdom. In addition, AaviGen showcased its dual-organ engineered AAV capsids suited, e.g., for neurological or muscular diseases with secondary involvement of the heart, such as Friedreich Ataxia or Muscular dystrophies. The meeting (<https://cell-and-gene-therapy.b2match.io/home>) is jointly organized by BIOPRO Baden-Württemberg, the UK Department for International Trade, Scottish Development International, Welsh Government, London & Partners and the cluster MedCity as well as the Northern Health Science Alliance.

“AaviGen’s proprietary novel engineered AAV capsids are key to our comprehensive strategy to develop broadly applicable curative AAV-based gene therapies for rare and common heart diseases.” stated Dr. Martin Busch, COO of AaviGen. “The further expanding engineered AAV vector portfolio is the foundation to develop our therapeutic products and build partnerships in the rapidly growing field of DNA- and RNA-based treatments of cardiovascular and cardiopulmonary disorders” explicated Prof. Marc Lerchenmüller, AaviGen’s CFO. “We are extremely excited to see the growing results of our continued innovative work and the forward-looking investment made by Dietmar Hopp. 2023 will be a decisive part in AaviGen’s innovative journey.” said Prof. Patrick Most and Prof. Hugo Katus, CEO and CMO of AaviGen.

About AaviGen

AaviGen was founded in 2019 on the understanding that successful gene therapy requires optimized delivery of therapeutic targets to the diseased heart. AaviGen’s scientific approach is documented in numerous peer-reviewed scientific publications and validated by its founders’ track record in scientific innovations for the diagnosis and treatment of cardiac diseases, including gene therapy medicinal products. For more information, please see: www.aavigen.com

AaviGen Investor and Media Contact

Prof. Dr. Marc Lerchenmüller, Chief Financial Officer and Managing Director

AaviGen, Heidelberg, Germany

T: +49 6221 568900

M: +49 151 51646589

marc.lerchenmueller@aavigen.com



AaviGen's Forward-Looking Statements

This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the company’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.